ClearPoint Neuro, Inc. (NASDAQ:CLPT) said on October 14, 2026, that it plans to publish its financial results for the 2026 third quarter after the market close on Wednesday, October 28, 2026. The company will discuss the results with investors and analysts during a live broadcast later that day.
#Results review scheduled for October 28
The live review is scheduled to begin at 4:30 p.m. Eastern time, or 1:30 p.m. Pacific time. Participants can listen online or join by telephone at (877) 407-9034. Callers outside the U.S. or Canada can use (201) 493-6737.
A telephone replay is expected to be available shortly after the call and will remain accessible until November 27, 2026. The replay numbers are (877) 660-6853 for U.S. callers and (201) 612-7415 for callers outside the U.S. or Canada. The conference I.D. number is 413671.
ClearPoint Neuro also said an online archive of the broadcast will be posted on its Investor website.
#Company background
ClearPoint Neuro describes itself as a company that enables device, cell and gene therapy applications through navigation to the brain and spine. Its activities include established clinical products and pre-clinical development services for controlled drug and device delivery.
The company's flagship ClearPoint Neuro Navigation System has FDA clearance and is CE-marked. ClearPoint Neuro works with healthcare and research centres in North America, Europe, Asia and South America, as well as pharmaceutical and biotech companies, academic centres and contract research organisations.
The company said its solutions support direct delivery of therapeutics to the Central Nervous System in pre-clinical studies and clinical trials. It also provides support through a field-based clinical specialist team.
#Risks noted by ClearPoint Neuro
ClearPoint Neuro said statements about its plans, growth, strategies, future events and performance may be forward-looking statements. The company cautioned that actual results may differ materially from those statements.
Risks identified by the company include its ability to commercialise its products and services, achieve broader market acceptance, obtain and maintain regulatory clearances, and support wider adoption of intracranial administration of gene and cell therapies. Other risks include changes in the regulatory approval and market adoption of therapies being developed by biotech partners, continued use of the company's products by those partners, maintaining or establishing partnerships, and the future market for pre-clinical services.
The company also cited competition, reliance on third-party suppliers and manufacturers, supply chain disruptions and tariffs, intellectual property protection, indebtedness and required payments under outstanding notes, and the ability to raise additional capital when needed on acceptable terms. Additional risks include product liability claims, product recalls, cybersecurity incidents, inflation, interest rates, geopolitical events, and general economic, political and market conditions.
ClearPoint Neuro also identified uncertainty over whether the anticipated benefits of the IRRAS transaction will be realised and whether IRRAS can be integrated into the business as expected, along with possible differences between the expected and actual market potential of IRRAS products.
#Key Takeaways
- ClearPoint Neuro plans to release its 2026 third-quarter results after the market close on October 28, 2026.
- The results review is scheduled for 4:30 p.m. Eastern time, or 1:30 p.m. Pacific time, on the same day.
- Telephone participation and a replay will be available, with the replay scheduled to remain accessible until November 27, 2026.
- ClearPoint Neuro provides navigation products and development services for brain and spine procedures, including applications involving cell and gene therapies.
Original source: Read original article